Inhibitory Effects of Roscovitine on Proliferation and Migration of Vascular Smooth Muscle Cells In Vitro

• Published in: Journal of Huazhong University of Science and Technology. Medical sciences Vol. 34; no. 6; pp. 791 - 795
• Main Author: 张双双 王伟 赵崇强 谢敏杰 李闻宇 杨向俐 吕家高
• Format: Journal Article
• Language: English
• Published: Heidelberg Huazhong University of Science and Technology 01.12.2014; Department of Cardiovascular Medicine, The Central Hospital of Wuhan, Wuhan 430014, China%Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China%Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
• Subjects: Animals; Cell Cycle - drug effects; Cell Line; Cell Movement - drug effects; Graft Occlusion, Vascular - drug therapy; Graft Occlusion, Vascular - metabolism; Graft Occlusion, Vascular - pathology; Medicine; Medicine & Public Health; Muscle, Smooth, Vascular - metabolism; Muscle, Smooth, Vascular - pathology; Myocytes, Smooth Muscle - metabolism; Myocytes, Smooth Muscle - pathology; Protein Kinase Inhibitors - pharmacology; Purines - pharmacology; Rats; 体外增殖; 抑制作用; 流式细胞仪; 浓度依赖性; 细胞周期蛋白依赖性激酶; 细胞生长; 血管平滑肌细胞; 迁移; cell migration; restenosis; cell proliferation; cell cycle; vascular smooth muscle cells; roscovitine
• ISSN: 1672-0733; 1993-1352
• DOI: 10.1007/s11596-014-1354-5

Abnormal proliferation and migration of vascular smooth muscle cells （VSMCs） are the major cause of in-stent restenosis （ISR）. Intervention proliferation and migration of VSMCs is an im- portant strategy for antirestenotic therapy. Roscovitine, a second-generation cyclin-dependent kinase in- hibitor, can inhibit cell cycle of multiple cell types. We studied the effects of roscovitine on cell cycle distribution, proliferation and migration of VSMCs in vitro by flow cytometry, BrdU incorporation and wound healing assay, respectively. Our results showed that roscovitine increased the proportion of Go/G1 phase cells after 12 h （69.57±3.65 vs. 92.50±1.68, P=0.000）, 24 h （80.87±2.24 vs. 90.25±0.79, P=0.000） and 48 h （88.08±3.86 vs. 88.87±2.43, P=-0.427） as compared with control group. Roscovifine inhibited proliferation and migration of VSMCs in a concentration-dependent way. With the increase of concen- tration, roscovitine showed increased capacity for growth and migration inhibition. Roscovitine （30 μmol/L） led to an almost complete VSMCs growth and migration arrest. Combined with its low toxicity and selective inhibition to ISR-VSMCs, roscovitine may be a potential drug in the treatment of vascular stenosis diseases and particularly useful in the prevention and treatment of ISR.